James Yun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4062978/publications.pdf

Version: 2024-02-01

759190 501174 29 839 12 28 citations h-index g-index papers 32 32 32 904 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Reducing severe cutaneous adverse and type B adverse drug reactions using preâ€stored human leukocyte antigen genotypes. Clinical and Translational Allergy, 2022, 12, e12098.	3.2	4
2	Severe Delayed-Onset Neutropenia Induced by Ocrelizumab. Neurohospitalist, The, 2021, 11, 59-61.	0.8	10
3	A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 929-936.e7.	3.8	18
4	The role of intravenous immunoglobulin in treatment of refractory Felty syndrome c. Internal Medicine Journal, 2021, 51, 303-304.	0.8	1
5	Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3442-3449.e3.	3.8	11
6	Disseminated sarcoidosis involving lymph nodes, bone and spleen with progressive cardiac sarcoidosis on 18F-FDG PET/CT and cardiac MRI. Radiology Case Reports, 2021, 16, 3610-3613.	0.6	0
7	A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 696-703.	3.8	24
8	Multicenter Australian Study to Determine Criteria for Low- and High-Risk Penicillin Testing in Outpatients. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 681-689.e3.	3.8	39
9	Outcomes of Cancer Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: CardioOncology, 2020, 2, 506-508.	4.0	4
10	HLA-DRB1*15. Investigative Radiology, 2020, 55, 304-309.	6.2	11
10	HLA-DRB1*15. Investigative Radiology, 2020, 55, 304-309. Behçet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643.	0.8	11
	Behçet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50,		
11	Behçet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643.	0.8	1
11 12	Behçet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643. Severe infusion reaction due to nivolumab: A case report. Cancer Reports, 2020, 3, e1246. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine,	0.8	8
11 12 13	Behçet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643. Severe infusion reaction due to nivolumab: A case report. Cancer Reports, 2020, 3, e1246. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine, 2020, 180, 745. Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pacific Allergy, 2020, 10,	0.8 1.4 5.1	1 8 135
11 12 13	BehĀSet diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643. Severe infusion reaction due to nivolumab: A case report. Cancer Reports, 2020, 3, e1246. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine, 2020, 180, 745. Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pacific Allergy, 2020, 10, e8. Diagnostic procedures & Cancer Reports, 2020, 3, e1246.	0.8 1.4 5.1 1.3	1 8 135 15
11 12 13 14	Beh§et diseaseâ€associated rhabdomyolysis treated with infliximab. Internal Medicine Journal, 2020, 50, 642-643. Severe infusion reaction due to nivolumab: A case report. Cancer Reports, 2020, 3, e1246. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine, 2020, 180, 745. Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pacific Allergy, 2020, 10, e8. Diagnostic procedures & Diagn	0.8 1.4 5.1 1.3	1 8 135 15 8

#	Article	IF	CITATIONS
19	The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1261-1270.	3.8	15
20	Dapsoneâ€induced drug reaction with eosinophilia and systemic symptoms associated with HLAâ€B*13:01. Internal Medicine Journal, 2018, 48, 363-364.	0.8	10
21	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1059-1060.	3.8	29
22	Anaphylaxis to diphenylcyclopropenone during sensitization for wart treatment—A case report. JAAD Case Reports, 2018, 4, 872-873.	0.8	5
23	Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome. Annals of Allergy, Asthma and Immunology, 2017, 118, 726-728.	1.0	4
24	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138.	2.1	67
25	T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89.	1.3	38
26	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nature Reviews Rheumatology, 2016, 12, 235-242.	8.0	139
27	Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. International Archives of Allergy and Immunology, 2015, 168, 13-24.	2.1	71
28	Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01. Journal of Immunology, 2014, 192, 2984-2993.	0.8	136
29	Allergies. , 2014, , 323-328.		0